Investigation into the frequency of anti-immunoglobulin autoantibodies in humans that bind to GSK2862277 (a variable heavy chain domain antibody targeting human TNFR1) and the potential for dAb:autoantibody complexes to activate TNFR1 signalling.
Dr Andrew Bayliffe
Samples and data
Institution or company
The aim of the study is to explore the function of human anti-immunogloblin autoantibody responses and why they are present in humans.
Organisation: This study is organised by Dr Andrew Bayliffe from GlaxoSmithKline.